PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)
• PAX-101 demonstrated sustained improvements over placebo in the trial’s primary and several secondary endpoints and a favorable safet...